SOURCE: Aoxing Pharmaceutical

March 04, 2011 09:30 ET

Aoxing Pharmaceutical Company to Present at Rodman & Renshaw Annual China Investment Conference

NEW YORK, NY--(Marketwire - March 4, 2011) -  Aoxing Pharmaceutical (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced that the Company will be presenting at the Rodman & Renshaw Annual China Investment Conference.

Mr. Zhenjiang Yue, Chairman and CEO, and Mr. Bob Ai, Chief Financial Officer, will present at 11:05 AM local time on Monday, March 7, 2011 at Le Royal Meridien Shanghai. Mr. Yue and Mr. Ai will provide a review of recent pipeline developments, international collaborations, upcoming milestones and financial progress at Aoxing Pharma.

About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has a joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has strategic alliance partnerships with QRxPharma, Phoenix PharmaLabs, Inc and American Oriental Bioengineering, Inc. For more information, please visit:

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2009, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact Information

    Aoxing Pharmaceutical Company:
    Bob Ai
    Chief Financial Officer

    Investor Relations:
    The Trout Group
    Brian Korb